MARKET

XBIT

XBIT

Xbiotech
NASDAQ
9.25
-0.25
-2.63%
After Hours: 9.52 +0.27 +2.92% 18:06 04/12 EDT
OPEN
9.37
PREV CLOSE
9.50
HIGH
9.52
LOW
9.09
VOLUME
53.87K
TURNOVER
0
52 WEEK HIGH
9.96
52 WEEK LOW
3.050
MARKET CAP
281.67M
P/E (TTM)
-11.4650
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at XBIT last week (0401-0405)?
Weekly Report · 5d ago
BUZZ-Tesla up after Musk says Tesla will unveil Robotaxi in August
Shares of electric vehicle maker Tesla rise 4.3% to $170.31 after the bell. Tesla will unveil "Robotaxi" on Aug. 8, Elon Musk says. TSLA stock had fallen 33% YTD. Musk says Tesla will unveiled Robotaxi in August.
Reuters · 04/05 21:23
Weekly Report: what happened at XBIT last week (0325-0329)?
Weekly Report · 04/01 09:14
Weekly Report: what happened at XBIT last week (0318-0322)?
Weekly Report · 03/25 09:14
XBiotech Inc.'s (NASDAQ:XBIT) market cap up US$24m last week, benefiting both retail investors who own 44% as well as insiders
Retail investors own 44% of XBiotech Inc. (NASDAQ:XBIT) The top 7 shareholders own 50% of the company, with an insider ownership of 44% in the company. The majority of shares are owned by the general public, with no institutional investors. XBi biotech has a market capitalization of US$217m. The company's CEO John Simard is the biggest shareholder with 22% of shares outstanding. X biotech's insider ownership could be a cause for concern, but there are also three warning signs for investors.
Simply Wall St · 03/20 10:03
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
XBiotech reported earnings per share of -16 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. XBiotech is a biotechnology company that has not reported any revenue in the last three months of the year .
Investorplace · 03/18 19:53
BUZZ-Tesla to hike Model Y prices in Europe, shares up
Tesla shares rise 3% to $168.4 premarket after electric vehicle maker says will raise prices of Model Y cars in parts of Europe. Model Y prices to be increased by about $2,177 in some European countries effective March 22. Goldman Sachs cuts PT to $190 from $220.
Reuters · 03/18 10:14
Weekly Report: what happened at XBIT last week (0311-0315)?
Weekly Report · 03/18 09:14
More
About XBIT
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Webull offers XBiotech Inc stock information, including NASDAQ: XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.